<table class="naaccr-summary-table naaccr-borders">
    <tr>
        <th class="naaccr-summary-header naaccr-borders">Item #</th>
        <th class="naaccr-summary-header naaccr-borders">Length</th>
        <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
        <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Column #</th>
    </tr>
    <tr>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1021</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">15</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">AJCC</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2018</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">18</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1218 - 1232</td>
    </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.ajccTnmPostTherapyT<br/><br/>


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div>
<div class='content chap10-para'>Detailed site-specific codes for the postneoadjuvant therapy tumor (T) as defined by AJCC.<br/><br/>Clinical, pathological, and postneoadjuvant therapy stage data are given three separate areas in the NAACCR Data Exchange Record Layout.
</div>
<div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div>
<div class='content chap10-para'>CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.<br/><br/>Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known following the completion of neoadjuvant therapy (satisfying the definition for that disease site) and planned postneoadjuvant therapy surgical resection.
</div>
<div class='content chap10-para'><strong>Codes (in addition to those published in the AJCC Cancer Staging Manual)</strong></div>
<div class='content chap10-para'>
    <table>
        <tr class='code-row'>
            <td class='code-nbr'>88</td>
            <td class='code-desc'>Not applicable, no code assigned for this case in the current AJCC Staging Manual.</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>Blank</td>
            <td class='code-desc'>This field is left blank if no information at all is available to code this item.</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr' colspan='2'></td>
        </tr>
    </table>
</div>
<div class='content chap10-para'><em>Note</em>: See the AJCC Cancer Staging Manual, current edition for site-specific categories for the TNM categories and stage groups. See the CURRENT
    <em>STORE </em>manual for specifications for codes and data entry rules.
</div>